Potent, p53-independent induction of NOXA sensitizes MLL-rearranged B-cell acute lymphoblastic leukemia cells to venetoclaxKlaudyna Fidyt, Małgorzata Firczuk, Magdalena Winiarska et al.|Oncogene|2022Cited by 18
Abstract 3324: Optimizing the therapeutic potential of tyrosine kinase inhibitors in chemo-immunotherapy of B-cell acute lymphoblastic leukemia involving rituximabKrzysztof Domka, Małgorzata Firczuk, Martyna Poprzeczko et al.|Cancer Research|2022Cited by 1
Asciminib stands out as the superior tyrosine kinase inhibitor to combine with anti-CD20 monoclonal antibodies for the treatment of CD20+ Philadelphia-positive B-cell precursor acute lymphoblastic leukemia in preclinical modelsKrzysztof Domka, Małgorzata Firczuk, Agnieszka Dąbkowska et al.|Haematologica|2024Cited by 1
Pharmacological Induction of NOXA Sensitizes High-Risk B Cell Acute Lymphoblastic Leukemia Cells to VenetoclaxKlaudyna Fidyt, Małgorzata Firczuk, Julia Cyran et al.|Blood|2020Cited by 0
P339: BOOSTING THE EFFICACY OF CD20-TARGETING IMMUNOTHERAPY IN B CELL ACUTE LYMPHOBLASTIC LEUKEMIAMartyna Poprzeczko, Małgorzata Firczuk, Krzysztof Domka et al.|HemaSphere|2022Cited by 0